当前位置: 首页 > 期刊 > 《世界华人消化杂志》 > 2007年第18期
编号:11495482
罗格列酮对小鼠日本血吸虫病肝纤维化基质金属蛋白酶-2的影响
http://www.100md.com 2007年6月28日 谌 辉, 张景辉, 刘文琪, 贺永文
过氧化物酶体增殖物激活受体γ;肝纤维化;MMP-2;TIMP-2,谌辉,贺永文,张景辉,刘文琪,通讯作者:,Effectsofrosiglitazoneonmatrixmetalloproteinase-2inmicewiths
第1页

    参见附件(800KB,4页)。

     谌辉, 贺永文, 华中科技大学同济医学院附属协和医院传染科 湖北省武汉市 430030

    张景辉,
华中科技大学同济医学院附属协和医院外科实验室 湖北省武汉市 430030

    刘文琪,
华中科技大学同济医学院寄生虫学教研室 湖北省武汉市 430022

    湖北省自然科学基金, No. 2005ABA170

    通讯作者:
谌辉, 430030, 湖北省武汉市, 华中科技大学同济医学院附属协和医院传染科. chenhui0515@yahoo.com.cn

    电话: 027-85726132

    收稿日期: 2007-03-23 接受日期: 2007-05-11

    Effects of rosiglitazone on matrix metalloproteinase-2 in mice with schistosomiasis and liver fibrosis

    
Hui Chen, Jing-Hui Zhang, Wen-Qi Liu, Yong-Wen He

    Hui Chen, Yong-Wen He,
Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

    Jing-Hui Zhang,
Department of Surgical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

    Wen-Qi Liu,
Department of Parasitology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

    Supported by:
The Natural Science Foundation of Hubei Province, No. 2005ABA170

    Correspondence to:
Hui Chen, Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. chenhui0515@yahoo.com.cn

    Received:
2007-03-23 Accepted:2007-05-11

    Abstract

    AIM: To study the effects of rosiglitazone, a peroxisome proliferator-activator receptor (gamma) ligand, on serum levels of matrix metalloproteinase-2 (MMP-2) and the tissue inhibitor of metalloproteinase-2 (TIMP-2), along with the hepatic expression of MMP-2 and TIMP-2 mRNA in mice with liver fibrosis caused by Schistosoma japonicum infection.

    METHODS: Fifty mice were divided into five groups: one uninfected group (A), and four schistosomiasis groups (B-E): without any treatment (B), praziquantel treatment (C), rosiglitazone treatment (D), and rosiglitazone and praziquantel treatment (E) ......

您现在查看是摘要介绍页,详见PDF附件(800KB,4页)